Columvi (glofitamab-gxbm) - Roche
Columvi: Regulatory submission in Japan for r/r DLBCL in 2026 (Chugai) - Oct 27, 2026 - Q3 FY2026 Results: Regulatory submission in Japan for r/r MCL in 2028 
Japan filing • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Mantle Cell Lymphoma • Oncology
https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_5_77.pdf&src=[%0],[%1]&rep=137,77
 
Oct 27, 2026
 
 
9f913929-ec12-48aa-b6c5-dc118cef2460.png